Anti-Myosin Heavy Chain Targeting and Signaling
From 2007.igem.org
Amendelsohn (Talk | contribs) |
Amendelsohn (Talk | contribs) (→How It works) |
||
| Line 15: | Line 15: | ||
7) Shp2-mLexA-dnEN comes in close proximity to the dnaEC-VP16 fused to the c-terminal of the gp130i | 7) Shp2-mLexA-dnEN comes in close proximity to the dnaEC-VP16 fused to the c-terminal of the gp130i | ||
| - | 8) dnaEN and dnaEC, | + | 8) dnaEN and dnaEC, parts of the split intein system, undergo peptide processing resulting in the release of newly constituted fusion transcription factor mLexA-VP16 |
| - | 9) mLexA-VP16 translocates to the nucleus where it binds to minimal promoters containing lexA operators to switch on expression N-Cadherin, anti-apoptotic | + | 9) mLexA-VP16 translocates to the nucleus where it binds to minimal promoters containing lexA operators to switch on expression of cell-cell interaction proteins such as N-Cadherin , anti-apoptotic proteins such as Bcl-XL,p35 and IAP and blood vessel growth factors such as VEGF. |
[[Image:scfv-circuit.jpg]] | [[Image:scfv-circuit.jpg]] | ||
Revision as of 03:06, 27 October 2007
How It works
1) Myosin Heavy Chain (MHC) is exposed on infarcted heart tissue.
2) scFv chimeric receptor to MHC binds to a repeated domain of MHC
3) EporD2 facilitates the dimerization of the chimeric receptors
4) EporTM mutant version inhibits ligand independent dimerization of the chimeric receptors
5) gp130i becomes activated and JAK's phosphorylate tyrosines on gp130i, including Y759.
6) Shp2-mLexA-dnEN binds to phosphorylated Y759 of gp130i
7) Shp2-mLexA-dnEN comes in close proximity to the dnaEC-VP16 fused to the c-terminal of the gp130i
8) dnaEN and dnaEC, parts of the split intein system, undergo peptide processing resulting in the release of newly constituted fusion transcription factor mLexA-VP16
9) mLexA-VP16 translocates to the nucleus where it binds to minimal promoters containing lexA operators to switch on expression of cell-cell interaction proteins such as N-Cadherin , anti-apoptotic proteins such as Bcl-XL,p35 and IAP and blood vessel growth factors such as VEGF.
